PSA screening and elderly men. Singer EA, Penson DF, Palapattu GS (2007) JAMA 297: 949; author reply 949-50 Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Perez-Pinera P, Ousterout DG, Brunger JM, Farin AM, Glass KA, Guilak F, Crawford GE, Hartemink AJ, Gersbach CA (2013) Nat Methods 10: 239-42 Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS (2016) J Clin Oncol 34: 2098-106 Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) J Natl Cancer Inst 94: 981-90 Prostate cancer and the Will Rogers phenomenon. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, Fine J (2005) J Natl Cancer Inst 97: 1248-53 A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells. Moad M, Pal D, Hepburn AC, Williamson SC, Wilson L, Lako M, Armstrong L, Hayward SW, Franco OE, Cates JM, Fordham SE, Przyborski S, Carr-Wilkinson J, Robson CN, Heer R (2013) Eur Urol 64: 753-61 Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial. Fowke JH, Howard L, Andriole GL, Freedland SJ (2014) Eur Urol 66: 1133-8 Overdiagnosis and overtreatment of prostate cancer. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R (2014) Eur Urol 65: 1046-55 NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ (2004) Cancer Res 64: 5489-95 The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Clark DE, Errington TM, Smith JA, Frierson HF, Weber MJ, Lannigan DA (2005) Cancer Res 65: 3108-16 Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ (2004) Clin Cancer Res 10: 1219-25 Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia. Hameed O, Humphrey PA (2006) Mod Pathol 19: 899-906 Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Fowke JH, Signorello LB, Chang SS, Matthews CE, Buchowski MS, Cookson MS, Ukoli FM, Blot WJ (2006) Cancer 107: 2361-7 Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD (2003) Cancer 98: 496-503 Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM (2006) Cancer 107: 1093-100 Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. Barocas DA, Grubb R, Black A, Penson DF, Fowke JH, Andriole G, Crawford ED (2013) Cancer 119: 2223-9 Upstream stimulatory factor 2, a novel FoxA1-interacting protein, is involved in prostate-specific gene expression. Sun Q, Yu X, Degraff DJ, Matusik RJ (2009) Mol Endocrinol 23: 2038-47 ARF represses androgen receptor transactivation in prostate cancer. Lu W, Xie Y, Ma Y, Matusik RJ, Chen Z (2013) Mol Endocrinol 27: 635-48 The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A, Rennie PS, Matusik RJ (2003) Mol Endocrinol 17: 1484-507 Use of thiazolidinediones does not affect prostate-specific antigen levels in men with diabetes. Pini TM, Griffin MR, Roumie CL, Huizinga MM, Fowke JH, Greevy R, Liu X, Murff HJ (2009) Cancer Epidemiol Biomarkers Prev 18: 1937-8 Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA (2003) Mol Cancer Res 1: 385-92 Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion. Ishii K, Otsuka T, Iguchi K, Usui S, Yamamoto H, Sugimura Y, Yoshikawa K, Hayward SW, Hirano K (2004) Cancer Lett 207: 79-87 MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. David SN, Arnold Egloff SA, Goyal R, Clark PE, Phillips S, Gellert LL, Hameed O, Giannico GA (2018) Prostate 78: 616-622 Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions. Fong CJ, Sherwood ER, Braun EJ, Berg LA, Lee C, Kozlowski JM (1992) Prostate 21: 121-31 Differential transactivation by the androgen receptor in prostate cancer cells. Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave M, Sato N, Mawji NR, Rennie PS (1998) Prostate 36: 256-63 Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Xue BH, Zhang Y, Sosman JA, Peace DJ (1997) Prostate 30: 73-8 Reconstituted basement membrane promotes morphological and functional differentiation of primary human prostatic epithelial cells. Fong CJ, Sherwood ER, Sutkowski DM, Abu-Jawdeh GM, Yokoo H, Bauer KD, Kozlowski JM, Lee C (1991) Prostate 19: 221-35 PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES. Fowke JH, Matthews CE (2010) Prostate 70: 120-5 Obesity and prostate cancer screening among African-American and Caucasian men. Fowke JH, Signorello LB, Underwood W, Ukoli FA, Blot WJ (2006) Prostate 66: 1371-80 A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. Smith JA, Chan RC, Chang SS, Herrell SD, Clark PE, Baumgartner R, Cookson MS (2007) J Urol 178: 2385-9; discussion 2389-90 What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. Barocas DA, Cowan JE, Smith JA, Carroll PR, CaPSURE Investigators (2008) J Urol 180: 1330-4; discussion 1334-5 The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L (2004) J Urol 171: 2250-4 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J (2007) J Urol 177: 932-6 Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. Albertsen PC, Hanley JA, Penson DF, Fine J (2004) J Urol 171: 2221-5 Early detection of prostate cancer: AUA Guideline. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL (2013) J Urol 190: 419-26 Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. Fong CJ, Sutkowski DM, Braun EJ, Bauer KD, Sherwood ER, Lee C, Kozlowski JM (1993) J Urol 149: 1190-4 Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? Phillips JJ, Hall MC, Lee WR, Clark PE (2007) Urol Oncol 25: 196-200 Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA (2011) Urol Oncol 29: 608-13 Prostate cancer screening between low-income African-American and Caucasian men. Fowke JH, Schlundt D, Signorello LB, Ukoli FA, Blot WJ (2005) Urol Oncol 23: 333-40 Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Perambakam S, Hallmeyer S, Reddy S, Mahmud N, Bressler L, DeChristopher P, Mahmud D, Nunez R, Sosman JA, Peace DJ (2006) Cancer Immunol Immunother 55: 1033-42
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.